Fetal Fraction of Cell-Free DNA in Noninvasive Prenatal Testing and Adverse Pregnancy Outcomes: A Nationwide Retrospective Cohort Study of 56,110 Pregnant Women
(Abstracted from Am J Obstet Gynecol 2024;231:244.e1–244.e18) Noninvasive prenatal testing (NIPT) for Down, Edwards, and Patau syndromes is widely available. Its accuracy depends on a sufficient amount of fetal cell-free DNA (cfDNA) in maternal plasma.
Authors
- Lidewij Henneman (ORCID: https://orcid.org/0000-0003-3531-0597)
- Marjan M. Weiss (ORCID: https://orcid.org/0000-0002-0936-1406)
- Neeltje Crombag (ORCID: https://orcid.org/0000-0002-6808-0874)
- Mireille N. Bekker (ORCID: https://orcid.org/0000-0002-7372-4291)
- Ewoud Schuit (ORCID: https://orcid.org/0000-0002-9548-3214)
- Jens Henrichs (ORCID: https://orcid.org/0000-0003-2238-4060)
- Erik A. Sistermans (ORCID: https://orcid.org/0000-0001-7187-4563)
- Ellis C. Becking (ORCID: https://orcid.org/0000-0003-0418-7880)
- Merryn Macville (ORCID: https://orcid.org/0000-0003-1675-2234)
- Diane Van Opstal (ORCID: https://orcid.org/0000-0002-3895-6775)
- P Scheffer (ORCID: https://orcid.org/0000-0001-9253-5341)
- Caroline J. Bax (ORCID: https://orcid.org/0000-0001-8150-2835)
- Elles M. J. Boon
Publication Details
- Journal
- Obstetrical & Gynecological Survey
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1097/ogx.0000000000001376
- Primary Topic
- Prenatal Screening and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00